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AbstrACt
Introduction Although guided forms of internet-based 
cognitive–behavioural therapy (iCBT) result in a substantial 
reduction in depression, it seems that the most scalable 
way to deliver iCBT is without guidance. However, direct 
evidence on the comparison between guided and self-
guided iCBT is scarce. Moreover, it is unclear which 
types of patients may benefit more from each of these 
two forms of iCBT. Network meta-analysis (NMA) using 
individual participant data (IPD) offers a way to assess 
the relative efficacy of multiple (>2) interventions. 
Moreover, it maximises our power to detect patient-level 
characteristics (covariates) that have an important effect 
on the efficacy of interventions. This protocol describes the 
procedures of an IPD-NMA, which aims at examining the 
relative efficacy of guided compared with self-guided iCBT 
and at identifying predictors and moderators of treatment 
outcome.
Methods and analysis We will use an existing database 
on psychotherapies for adult depression to identify eligible 
studies. This database has been updated up to 1 January 
2018, through literature searches in PubMed, Embase, 
PsycINFO and Cochrane Library. The outcome of this 
IPD-NMA is reduction in depressive symptoms severity. 
We will fit the model in a Bayesian setting. After fitting 
the model, we will report the relative treatment effects 
for different types of patients, and we will discuss the 
clinical implications of our findings. Based on the results 
from the IPD-NMA model, we will develop and validate a 
personalised prediction model, aiming to provide patient-
level predictions about the effects of the interventions.
Ethics and dissemination An ethical approval is not 
required for this study. The results will be published in 
a peer-review journal. These results will guide clinical 
decisions about the most efficient way to allocate iCBT 
resources, thereby increasing the scalability of this 
innovative therapeutic approach.
IntroduCtIon
Depression is one of the most common 
mental health disorders, with debilitating 
consequences for individuals and society.1 
Lifetime prevalence rates of depression range 
from 6.5% in Japan to 21% in France,2 while 
according to the WHO, over 300 million 
people suffer from this disorder worldwide.3 
Depression is a highly prevalent and a very 
disabling disorder, which is expected to be 
the largest contributor to the global burden 
of disease by 2030.4 These alarming obser-
vations underline the necessity to provide 
effective treatment to all individuals with 
depression in a timely manner.
Although there are effective treatments for 
depression, a considerable number of those 
affected do not seek or receive help for their 
condition.5 6 Barriers to treatment include, 
among others, the high cost of treatment, 
the limited availability of trained clinicians 
and the fear of stigmatisation.7 8 Therapeutic 
approaches, such as internet-based interven-
tions, have the potential to overcome many of 
strengths and limitations of this study
 ► We will conduct an individual patient data network 
meta-analyses to examine all available evidence on 
the comparison between guided and self-guided in-
ternet-based cognitive–behavioural therapy (iCBT) 
for depression.
 ► We will develop and validate a personalised predic-
tion model indicating who may benefit from guided 
and who from self-guided iCBT for depression.
 ► This will be the largest individual patient data me-
ta-analysis, which will directly compare the effects 
of guided and self-guided iCBT using an innovative 
methodological approach.
 ► It is possible that we will not receive all primary 
datasets from all eligible trials. However, we expect 
to gather the majority of existing data.
 ► There is also a possibility that studies have not col-
lected all variables of interest. Thus, we will not be 
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the treatment barriers, thereby increasing access to treat-
ment. A growing body of literature suggests that inter-
net-based cognitive–behavioural therapy (iCBT) leads to 
substantial improvements on depression.9–13 It can either 
be delivered with some form of therapeutic guidance 
(guided interventions) or without any support related to 
the therapeutic content (self-guided interventions).14 15
It has been shown that for the treatment of depression, 
guided forms of iCBT have larger effects than controls13 
and similar effects with face-to-face psychotherapy.16 
Moreover, it has been shown that individuals with depres-
sion are more likely to respond and remit after receiving 
guided iCBT13 while they have a lower probability of 
deteriorating.17 Despite these promising outcomes, the 
provision of guided iCBT depends on the availability 
of therapists or coaches. Thus, scaling-up guided iCBT 
remains a challenge, especially in low-resource settings.18 
Furthermore, it may also not be necessarily cost-effec-
tive in high-income countries. Thus, it might be the case 
that the most efficient way to scale-up iCBT would be to 
provide it without therapeutic guidance.18
Clinical trials that have examined self-guided forms 
of iCBT have shown a wide range of possible ther-
apeutic effects on depression varying from zero up 
to moderate effects.19–22 These different outcomes 
have been summarised in a recent individual patient 
data (IPD) meta-analysis, which has shown that self-
guided iCBT results in small effects in treating depres-
sion when compared with control conditions.23 These 
effects, however, are much smaller in magnitude to those 
observed in trials comparing guided iCBT to controls.12 
In light of this difference in the effect sizes, it has been 
suggested that guided iCBT is more effective compared 
with unguided iCBT.24 25 However, this assumption is 
mostly based on indirect comparisons, while evidence 
derived from direct comparisons is scarce.26 Therefore, 
it remains unclear whether guided and self-guided iCBT 
result in significantly different outcomes in treating 
depression.25
Furthermore, no study has ever examined who may 
benefit from guidance and who may not. For instance, 
individuals with severe depression may benefit from 
guidance, while those with mild symptoms may be more 
capable of following the intervention content without 
support. Understanding for whom guided or self-guided 
iCBT is more effective will help us in allocating therapy 
resources in the most efficient way, thereby increasing 
iCBT’s scalability. It is, thus, important to further examine 
the effects of guided versus self-guided iCBT and to gain 
a deeper understanding of who may benefit more from 
which form of this therapeutic approach.
Individual randomised controlled trials (RCTs) are 
expected to be underpowered to answer either of these 
two questions. Conventional pair-wise meta-analyses that 
use aggregated (study-level) data may be able to overcome 
the issue of statistical power if enough direct comparison 
trials are available, but even in this case, they cannot iden-
tify which patient-level characteristics affect the efficacy 
of the interventions. Novel meta-analytic approaches 
enable us to synthesise IPD and use both direct and indi-
rect treatment comparisons, that is, comparisons via a 
common comparator. IPD network meta-analyses (IPD-
NMA) offer a way to maximise the statistical power to 
detect treatment-covariate interactions and to provide an 
overall estimate of treatment effects, using information 
from trials involving different treatment comparisons.27 28 
In the current study, we aim to conduct an IPD-NMA to 
examine the relative efficacy of guided compared with 
self-guided iCBT in treating adult depression and to iden-
tify who may benefit more from each type of iCBT. We 
also aim to develop and validate a personalised prediction 
model. This will use information on a particular patients’ 
characteristics and will provide a prediction of the 
progression of the depression severity under guided or 




We will use an existing database of psychological treat-
ments for depression that has been described in detail 
elsewhere29 and that has been used in a series of published 
meta-analyses ( www. evid ence base dpsy chot herapies. org). 
This database is annually updated through comprehen-
sive literature searches in the bibliographic databases of 
PubMed, PsycINFO, Embase and the Cochrane Library. 
The latest search was performed from database inception 
to 1 January 2018. The search strings use a combination 
of Index and free terms of psychological treatments and 
depression (full strings of PubMed are provided in online 
supplementary appendix A). In these searches, two inde-
pendent reviewers (PC and EK) examined 14 290 titles 
and abstracts. From these 14 290 abstracts, 2092 full-text 
papers were retrieved and examined for possible inclu-
sion in the database. In addition to this database, we 
also checked the primary studies from meta-analyses of 
psychological treatments for depression to ensure that 
no published studies will be missed. We will also ask the 
primary authors of the eligible studies if they are aware of 
any other study that has been conducted in the examined 
field.
Eligibility criteria
In the present IPD-NMA, we will include RCTs that exam-
ined at least two of the following interventions: guided 
iCBT, self-guided iCBT or a control comparison condi-
tion for treating adults with depression. No language 
restrictions will be applied. The participants, interven-
tions, comparisons and outcomes will be explained in 
detail in the following.
Participants
Participants will be adults (≥18 years of age) with depres-
sion based on either a diagnosis established by a clinical 
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Interview30) or elevated depressive symptoms rated by any 
self-report outcome measure (eg, Beck Depression Inven-
tory (BDI); based on the cut-off scores originally used by 
the eligible studies).31 Studies including participants with 
comorbid common mental health disorders will not be 
excluded as long as they include people with depression 
primarily. However, we will exclude studies on comorbid 
depression and cognitive impairment/dementia or severe 
mental illness (eg, bipolar disorder and psychosis). We 
will also exclude studies with a primary focus on a medical 
illness.
Interventions
We will include only studies that examined a guided 
and/or a self-guided CBT delivered via the internet. We 
have based the definition of CBT on an expert taxonomy 
of psychotherapy for depression.32 According to this 
taxonomy, CBT is defined as a psychotherapeutic inter-
vention that employs cognitive restructuring as either a 
core element or an important component of the treat-
ment.32 Therefore, interventions falling under the 
broader CBT umbrella (eg, problem solving therapy and 
behavioural activation) will be excluded. This study also 
focuses on interventions delivered via the internet, so that 
older studies that used stand-alone computerised CBT 
will not be included. Moreover, we will exclude studies 
with face-to-faced contact (eg, blended interventions or 
teleconferences).
In the present IPD-NMA, guided iCBT is defined as an 
intervention based on CBT self-help material and deliv-
ered via the internet with some form of guidance related 
to the therapeutic content. This guidance can be provided 
either by a professional (psychiatrist or clinical psycholo-
gist) or e-coaches (eg, trained clinical psychology master 
students or trained paraprofessionals), and it is provided 
by electronic means (eg, email or brief telephone calls). 
Self-guided iCBT is defined as an intervention provided 
without any support related to the therapeutic content. 
Studies focusing on self-guided iCBT with technical 
support (related to the online platform use) will be clas-
sified as self-guided iCBT interventions with technical 
support. Email or telephone support by administrative 
staff will be classified here. The effect of self-guided iCBT 
with or without technical support separately will be exam-
ined in a subgroup analysis. Face-to-face contact with 
therapists is allowed for baseline interview only. Studies 
focusing on blended iCBT (combined internet and face-
to-face CBT in one treatment protocol) will be excluded. 
In a blended iCBT, patients have face-to-face sessions with 
psychotherapists. Thus, we decided to exclude blended 
iCBT as it differs substantially from stand-alone online 
interventions with minimal therapeutic contact.
Comparisons
Studies will be included in the present IPD-NMA if they 
compare guided or self-guided iCBT to each other and/
or to an inactive control condition, such as waiting list, 
attention placebo, no treatment and treatment as usual 
(TAU).
Therefore, the network of treatments in our IPD-NMA 
will include guided iCBT, self-guided iCBT, waiting list, 
attention placebo no treatment and TAU.
outcomes
Our primary outcome will be post-treatment depression 
symptom severity on a continuous scale. We will include 
studies using a depression outcome measure, such as the 
BDI, the Center of Epidemiological Studies Depression 
Scale33 or the Patient Health Questionnaire-9.34 If a study 
uses more than one depression measure, preference will 
be given to the measure reported by the majority of the 
included studies. In case a study reports two or more 
outcome measures, none of which are used by the rest 
of the included studies, preference will be given to the 
measure listed as primary in this study. For the IPD-NMA, 
if the studies use different outcome measures, they will be 
converted into the most commonly used scale using the 
established conversion algorithms.35 36 Outcomes will be 
extracted at pretreatment/post-treatment and follow-up 
(at ≥6 months postrandomisation). To assess long-term 
outcomes, we will examine outcomes at ≥6 months 
postrandomisation. If a study includes multiple follow-up 
time points, we will use the longer follow-up assessment 
provided.
Prognostic factors and effect modifiers of treatment outcome
In this study, we will start from a wide range of patient-
level variables, and we will explore their role as either 
prognostic factor (ie, variable that affects the disease 
progression equally for all the treatments in the network) 
or effect modifiers (ie, variables that have an impact 
on the relative effects of interventions). We will initially 
select candidate covariates based on previous literature 
findings and the availability of these variables in the 
included studies. For instance, previous IPD meta-anal-
yses have shown that people with higher depressive symp-
toms at the baseline have more chances to remit after 
guided iCBT.13 However, baseline depression severity is 
not associated with greater symptom improvement after 
self-guided iCBT.23 37 Moreover, it has been shown that 
ethnic minorities are less likely to respond to guided 
iCBT compared with natives.13 Therefore, we will collect 
data related to baseline depression severity and ethnicity. 
Nevertheless, given that existing literature on effect 
modifiers is limited, we will also collect data on variables 
that are available across the majority of the eligible trials. 
Next, we will collect and merge into the IPD dataset all 
participants’ sociodemographic and clinical characteris-
tics reported in the primary included trials. More specif-
ically, we will include demographics such as age, gender, 
ethnicity, educational background, marital status and 
employment.
Furthermore, according to existing literature, there 
are several factors associated with poor prognosis of 
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instance, it has been suggested that depression severity, 
comorbidity and number of previous episodes are asso-
ciated with depression prognosis.39 Thus, in the present 
IPD-NMA, we will collect and merge variables related to 
clinical characteristics of participants, such as depression 
severity at the baseline, number of previous depressive 
episodes, duration of depression, comorbid symptoms of 
other mental disorders (anxiety disorders, eating disor-
ders, alcohol misuse, insomnia, personality disorders 
and so on), comorbid physical illness (eg, diabetes, heart 
failure and so on), history of treatment and current use of 
antidepressant medications.
data collection and aggregation
We will build on an existing database of internet-based 
interventions for depression. This database already 
includes the majority of the eligible trials, and it has been 
used by two previous IPD meta-analyses on guided13 and 
self-guided23 internet-based interventions for depres-
sion. Trials’ corresponding authors will be contacted for 
permission to use their primary datasets. In case a corre-
sponding author cannot be reached, a follow-up email 
will be sent to the senior author of the trial. Reminders 
will be sent after 2 weeks, and if necessary, after 1 month. 
If no response is received after 1 month, the trial will be 
excluded as unavailable. Authors will be asked to provide 
their trial outcome raw data as well as data related to 
potentially important covariates (as described above). 
We will also collect study-level variables based on the 
published reports.
After collecting all primary datasets, two independent 
reviewers will perform an initial data check to ensure 
that each dataset matches with its published report. 
This initial data check will involve checking sociodemo-
graphic (eg, percentage of males and females) and clin-
ical characteristics (eg, mean of depression scale scores 
at the baseline) and comparing those characteristics to 
the numbers reported on the published papers. In case 
the numbers do not match, we will contact the authors of 
the trials for clarifications. After each dataset is checked, 
two independent reviewers will merge the variables into 
the IPD dataset. Disagreements in coding will be resolved 
through discussion.
risk of bias assessment
We will assess the risk of bias of the included studies in 
the following domains: (A) the random sequence genera-
tion, (B) the concealment of allocation to conditions, (C) 
the selective outcome reporting and (D) other possible 
sources of bias (eg, extreme baseline differences).40 The 
criteria for judgement will be based on the risk of bias 
assessment tool of the Cochrane Collaboration, which 
systematically assesses possible risk of bias in RCTs related 
to selection, performance, detection, attrition, reporting 
and other sources.40 In addition to the four domains 
mentioned above, this tool originally evaluates (E) the 
prevention of knowledge of the allocation by participants, 
personnel (performance bias) and assessors (assessment 
bias) and (F) the handling of incomplete outcome 
data. However, blinding of participants and personnel 
(performance bias) is mostly not possible in psycho-
therapy research. Thus, we will not rate this item since all 
psychotherapeutic trials are at high risk of performance 
bias. Regarding incomplete outcome data, a study will 
consider at high risk of bias if it has overall >50% study 
dropout and >30% imbalance in missing values between 
groups. Two independent reviewers will first perform the 
risk of bias assessment based on the published reports. 
Disagreements will be solved through discussion. When 
the judgement is unclear risk of bias, we will go back to 
the original authors for clarification.
Patient and public involvement
There was no patient or public involvement in the devel-
opment of this manuscript.
IPd-nMA model
We will employ a one-stage IPD network meta-regres-
sion model to synthesise our data, set in a Bayesian back-
ground. Let us assume that patient i in study j received 
treatment treatij and that for this patient we have vectors 
of prognostic factors (PFij) and effect modifiers (EMij). To 
facilitate convergence of the model, all continuous covari-
ates will be standardised by subtracting the overall mean 
and dividing by their corresponding standard deviation 
across all trials. When presenting the final results, we will 
back-transform the covariates to their original scales. For 
some patients, some of the covariates may be missing. For 
each covariate we will use a study-specific distribution to 
stochastically impute missing values, assuming that covari-
ates are missing at random. For example, if for patient i 
in study j we have no information on his/her age, we will 









. For continuous 
covariates, we will use normal distributions; for binary 
covariates, we will use a Bernoulli distribution and so on.
Next, let us assume that for each patient we observe a 
(continuous) outcome Yij. The model will be as follows:








uj + β PFij , if treatij = Tref
uj + β PFij + γ treatij
EMij + dtreatij , i , if treatij ̸= Tref   
In this expression, Tref is the reference treatment of the 
network, which we will take it to be no treatment. Sj
2 is 
the study-specific variance of the outcome. β is the vector 
of regression coefficients associated to prognostic factors. 
γtreatij is the vector of regression coefficients for effect 
modification, for the comparison treatij versus the refer-
ence. In essence, γtreatij captures the treatment–covariate 
interactions.
dtreatij,i is the average relative effect of treatij versus the 
reference treatment of the network in study i, that is, 
the relative effects for the case when effect modifiers are 
equal to zero. Note that the relative treatment effects 
are estimated separately in each study, that is, informa-
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directly together. The consistency equations required for 
NMA are automatically incorporated in the model. We 








, where τ will be the random effects SD. This will be set 
common for all comparisons versus the reference treat-
ment—a usual assumption in NMA.41 For the case of 
multiarm studies, we will include multivariate distri-
butions instead, taking into account the correlation of 
random effects. The parameter δtreatij corresponds to the 
pooled average treatment effects of treatment treatij versus 
the reference treatment of the network (no treatment).
Note that the imputation models for the missing 
covariates as well as the estimation model will be fitted 
simultaneously.
If we will not be able to fit a one-stage IPD NMA model, 
for example, due to computational constraints, we will fit 
a two-stage model IPD-NMA model instead. In case there 
is information on many patient-level covariates available 
in all the studies (or in the great majority of the studies), 
we will employ a variable selection method (such as 
Bayesian Lasso)42 to identify the most prominent ones. In 
our results, we will report the estimated relative treatment 
effects for various combinations of the covariate values.
Model fitting
We will fit our IPD-NMA model in OpenBUGS.43 We will 
use multiple independent chains for the analysis, and we 
will check convergence using the Brooks-Gelman-Rubin 
criterion.44 For all model parameters, we will use vague 
prior distributions. We will report the posterior median 
and 95% credible intervals. We will make all software 
codes used for our analyses freely available by uploading 
them in  github. com
building a prediction model
Using the estimated parameters of the IPD-NMA model, 
we will develop and validate a prediction model that will 
aim to provide personalised predictions about the effi-
cacy of the two interventions.45 The inputs of the model 
will be patient-specific values for prognostic factors and 
effect modifiers, and the output will be a prediction of the 
outcome under guided or self-guided iCBT. In order to 
cross-validate this model (ie, to assess its predictive perfor-
mance), we will follow an internal–external cross-valida-
tion method.46 More specifically, we will take one study 
out at a time, develop our model using the rest of the 
studies and test the model in the left out study by calcu-
lating the mean bias and the mean squared error of the 
predictions. We will repeat this procedure for all studies. 
We will report the mean bias and the mean squared error 
of the predictions across all studies. Via this approach, we 
will have a better understanding of the external validity of 
our prediction model, and we will visualise the expected 
heterogeneity regarding our model’s performance. If 
the overall performance of the model is deemed satis-
factory, we will develop our final model using all studies. 
In that case, we will also develop an online tool that will 
implement the model, so as to facilitate its use in clinical 
practice.45 Note that the main advantage of the internal–
external approach to cross-validation is that it does not 
waste any data, that is, all data will be used for the devel-
opment of the final model.
Missing data
The model imputes missing values on the covariates 
assuming they are missing at random. Also, it assumes 
that missing outcomes are missing at random. If the 
overall rate of missing outcome values in one study is 
large (>50%), we will exclude the study from our anal-
ysis. If a study has a large imbalance in missing values 
between the examined conditions (>30%), we will 
perform a sensitivity analysis where we will assume that 
the outcomes are missing not at random (MNAR), that is, 
we will fit a model where the probability of dropping out 
is associated with the unobserved outcome.28 If we deem 
that our results are not robust, that is, if we observe clini-
cally important differences between the primary analysis 
and the MNAR analysis, we will exclude studies with large 
imbalances.
heterogeneity and inconsistency
We will measure heterogeneity in the included studies 
by estimating a common heterogeneity parameter τ2. We 
will then compare this estimate with its empirical distri-
bution.47 48 We will assess the residual inconsistency in the 
network by estimating the difference between direct and 
indirect evidence in each loop of the network. We will do 
this by adding a number of inconsistency factors (IFs) to 
the model, depending on the number of closed loops in 
the network.
Publication bias and data availability bias
We will first examine small study effects by visually 
inspecting the contour enhanced funnel plots of pair-
wise meta-analyses for our outcome measure. We will also 
produce a comparison-adjusted funnel plot. If asymmetry 
is observed and if we have 10 or more studies per compar-
ison, we will test for publication bias using the Egger’s 
test49 for the continuous outcomes and Peters’s test for 
the binary ones.50 Moreover, it is possible that we will not 
receive all the datasets from the eligible studies. In this 
case, we will calculate the effects of the available and the 
unavailable trial to test whether they differ significantly. 
If we identify discrepancies, we will report them and take 
them into account in the interpretation of our outcomes.
Evaluation of certainty of evidence for the network estimates
We will assess the certainty of evidence of each network 
estimate of our two primary outcomes with the Grading 
of Recommendations, Assessment, Development and 
Evaluation (GRADE) framework, which characterises the 
quality of a body of evidence on the basis of the study 
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dIsCussIon
It has been claimed that guided iCBT is more effec-
tive than self-guided iCBT, based on indirect literature 
evidence, but this is largely an unexplored hypothesis.24 25 
It also remains unclear which patients may benefit from 
therapeutic guidance. In the present paper, we have 
outlined an IPD-NMA, which aims to examine the rela-
tive efficacy of guided compared with self-guided iCBT 
and identify who may benefit more from which form of 
iCBT. IPD meta-analyses maximise statistical power and 
precision, thereby allowing to detect a true effect size and 
to test prognostic factors and relative effect modifiers of 
treatment outcome. Furthermore, network meta-anal-
yses provide reliable evidence combining trials, which 
examine direct and indirect comparisons. The IPD-NMA 
is an innovative meta-analytic tool, which will enable us to 
test long-standing assumptions about the relative efficacy 
of guided versus self-guided iCBT for depression.
There are several limitations that should be expected. 
First, there is a possibility that we will not receive all 
primary datasets from all eligible trials. For instance, 
some of the trials on iCBT have been conducted more 
than 10 years ago. It is, therefore, possible that primary 
authors of these trials do not have access to the data-
sets anymore due to ethical restrictions regarding the 
maximum time that data can be stored. However, most 
of the iCBT trials are relatively recent; thus, we expect to 
receive the majority of the eligible datasets. Second, there 
is a possibility that studies have not examined all variables 
of interest. As a result, we will not be able to examine all 
moderators. Third, most of trials on iCBT have recruited 
participants through community, thereby limiting the 
generalisability of the outcomes to clinical samples.23
Nevertheless, we believe that the aforementioned bene-
fits of the IPD-NMA approach will counterbalance poten-
tial limitations. Therefore, we hope that this study will 
shed light on the comparison between guided and self-
guided iCBT and help us to gain a better understanding 
of who may benefit from these treatments. This knowl-
edge will guide clinical decisions about the most efficient 
way to allocate iCBT resources, thereby increasing the 
scalability of this innovative therapeutic approach.
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